Summary
Background: The response to first-line platinum doublets (cisplatin/etoposide) in small-cell lung cancer (SCLC) predicts the probability of subsequent response to second-line therapy. In general, the longer-lived the responses in first line, the better the outcome in second line, with the opposite prognosis for shorter-lived responses. Resistant SCLC is defined as relapse within 90 days of platinum-doublet treatment, and predictably correlates with shortened survival compared with sensitive disease, defined as relapse after 90 days. Case Report: We present a patient with platinum-resistant SCLC that was rechallenged with cisplatin/etoposide in the context of the clinical trial TRIPLE THREAT (NCT02489903) after treatment with, and progression on, the resistance-reversing anticancer agent RRx-001. Conclusion: The prolonged partial response of this platinum-resistant SCLC to reintroduced carboplatin/etoposide after RRx-001 belies and contradicts the prevailing orthodoxy in oncology that rechallenge with chemotherapy after the emergence of resistance is an exercise in futility and risk, which potentially exposes patients to toxicity without benefit.
Journal Section:
Novel Insights from Clinical Practice
References
1.
Abrams J, Doyle LA, Aisner J: Staging, prognostic features, and special considerations in small cell lung cancer. Semin Oncol 1988;15:261-227.
[PubMed]
2.
Aisner J: Extensive disease small cell lung cancer: The thrill of victory; the agony of defeat. J Clin Oncol 1996;14:658-665.
[PubMed]
3.
Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, Ramalingam SS: A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7:866-872.
[PubMed]
4.
Treat J, Huang CH, Lane SR, et al.: Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. Oncologist 2004;9:173-181.
[PubMed]
5.
von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF: Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014;32:4012-4019.
[PubMed]
6.
Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Degesys A, Kim MM, Oronsky AL, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C: RRx-001 in refractory small-cell lung carcinoma: A case report of a partial response after a third reintroduction of platinum doublets. Case Rep Oncol 2016;9:171-176.
[PubMed]
7.
Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA: Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res 2012;72:6362-6370.
[PubMed]
8.
Aronson JK: Rare diseases and orphan drugs. Br J Clin Pharmacol 2006;61:243-245.
[PubMed]
9.
Koinis F, Kotsakis A, Georgoulias V: Small cell lung cancer (SCLC): No treatment advances in recent years. Transl Lung Cancer Res 2016;5:39-50.
[PubMed]
10.
Stewart DJ: Topotecan in the first-line treatment of small cell lung cancer. Oncologist 2004;9 Suppl 6:33-42.
[PubMed]
11.
Weinmann M, Jeremic B, Bamberg M, et al.: Treatment of lung cancer in elderly part II: Small cell lung cancer. Lung Cancer 2003;40:1-16.
[PubMed]
12.
Merrill RM, Henson DE, Barnes M: Conditional survival among patients with carcinoma of the lung. Chest 1999;116:697-703.
[PubMed]
13.
Chute JP, Chen T, Feigal E, Simon R, Johnson BE: Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.
[PubMed]
14.
Antonia SJ, Bendell JC, Taylor MH, et al.: Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. J Clin Oncol 33, 2015 (suppl; abstr 7503).
15.
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009;15:7412-7420.
[PubMed]
16.
Das DS, Ray A, Das A, Song Y, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC: A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia 2016 [Epub ahead of print].
[PubMed]
17.
Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C: Immune reactivity and pseudoprogression or tumor flare in a serially biopsied neuroendocrine patient treated with the epigenetic agent RRx-001. Case Rep Oncol. 2016;9:164-170.
[PubMed]
18.
Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C: A partial response in an RRx-001-primed patient with refractory SCLC after a third introduction of platinum doublets. Case Rep Oncol 2016;9:285-289.
[PubMed]
© 2016 S. Karger GmbH, Freiburg
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.
